8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Century Therapeutics, Inc.(IPSC)Earnings, Financials & Key Ratios
IPSC•NASDAQ
Price updated Jun 19, 2026
AboutCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$109M+1556.8%
- EBITDA-$2M+98.4%
- Net Income-$10M+92.4%
- EPS (Diluted)-0.11+93.2%
- Gross Margin88%-12.0%
- EBITDA Margin-1.78%+99.9%
- Operating Margin-13.78%+99.3%
- Net Margin-8.78%+99.5%
- ROE-5.98%+91.8%
IPSC Key Insights
Century Therapeutics, Inc. (IPSC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 29.1%
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.1% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IPSC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IPSC Price & Volume
Century Therapeutics, Inc. (IPSC) stock price & volume — 10-year historical chart
Loading chart...
IPSC Growth Metrics
Century Therapeutics, Inc. (IPSC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years175.88%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-391.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-290.63%
Return on Capital
10 Years-33.77%
5 Years-31.94%
3 Years-30.83%
Last Year-7.05%
IPSC Recent Earnings
Century Therapeutics, Inc. (IPSC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.11+26.7%
$0.15
Rev
—
$3M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.25+10.7%
$0.28
Rev
—
$62,500
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.32+17.9%
$0.39
Rev
—
$83,330
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.38+0.0%
$0.38
Rev
—
$25,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.11vs $0.15+26.7% | —vs $3M |
| Q2 2026 | Mar 12, 2026 | $0.25vs $0.28+10.7% | —vs $62,500 |
| Q4 2025 | Nov 13, 2025 | $0.32vs $0.39+17.9% | —vs $83,330 |
| Q3 2025 | Aug 14, 2025 | $0.38vs $0.38+0.0% | —vs $25,000 |
Based on last 12 quarters of dataView full earnings history →
IPSC Peer Comparison
Century Therapeutics, Inc. (IPSC) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 | |||
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare IPSC vs Peers
Century Therapeutics, Inc. (IPSC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IPSC Income Statement
Century Therapeutics, Inc. (IPSC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 5.2M | 2.23M | 6.59M | 109.16M | 0 |
Revenue Growth % | - | - | - | - | -57.01% | 194.81% | 1556.76% | -100% |
Cost of Goods Sold | 249K | 1.75M | 4.58M | 0 | 0 | 0 | 13.1M | 3M |
COGS % of Revenue | - | - | - | - | - | - | 12% | - |
Gross Profit | -249K▲ 0% | -1.75M▼ 604.4% | -4.58M▼ 161.2% | 5.2M▲ 213.5% | 2.23M▼ 57.0% | 6.59M▲ 194.8% | 96.06M▲ 1357.9% | -3M▲ 0% |
Gross Margin % | - | - | - | 100% | 100% | 100% | 88% | - |
Gross Profit Growth % | - | -604.42% | -161.23% | 213.47% | -57.01% | 194.81% | 1357.93% | - |
Operating Expenses | 19.78M | 47.42M | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M | 113.94M |
OpEx % of Revenue | - | - | - | 2674.17% | 6656.87% | 2196.48% | 101.78% | - |
Selling, General & Admin | 5.52M | 7.74M | 14.65M | 31.86M | 34.71M | 33.16M | 24M | 22.18M |
SG&A % of Revenue | - | - | - | 612.75% | 1552.84% | 503.19% | 21.99% | - |
Research & Development | 14.27M | 39.68M | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M | 83.18M |
R&D % of Revenue | - | - | - | 1869.07% | 4148.1% | 1627.62% | 87.64% | - |
Other Operating Expenses | 0 | 0 | 0 | 10M | 21.36M | 4.33M | -8.57M | 2M |
Operating Income | -20.03M▲ 0% | -49.18M▼ 145.5% | -94.88M▼ 92.9% | -133.83M▼ 41.0% | -146.55M▼ 9.5% | -138.14M▲ 5.7% | -15.04M▲ 89.1% | -116.94M▲ 0% |
Operating Margin % | - | - | - | -2574.17% | -6556.87% | -2096.48% | -13.78% | - |
Operating Income Growth % | - | -145.47% | -92.95% | -41.05% | -9.5% | 5.74% | 89.11% | - |
EBITDA | -19.78M | -47.42M | -90.3M | -125.39M | -133.5M | -124.83M | -1.94M | -104.06M |
EBITDA Margin % | - | - | - | -2411.83% | -5973.24% | -1894.57% | -1.78% | - |
EBITDA Growth % | - | -139.7% | -90.42% | -38.86% | -6.47% | 6.49% | 98.45% | -437.68% |
D&A (Non-Cash Add-back) | 249K | 1.75M | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M | 12.88M |
EBIT | -244.77M | -53.19M | -94.51M | -129.64M | -134.25M | -124.78M | -15.04M | -110.18M |
Net Interest Income | 1.21M | 323K | -377K | 2.99M | 12.14M | 13.01M | 7.35M | 6.94M |
Interest Income | 1.21M | 704K | 898K | 2.99M | 12.68M | 13.01M | 7.35M | 6.94M |
Interest Expense | 0 | 381K | 1.27M | 0 | 540K | 0 | 0 | 0 |
Other Income/Expense | -224.74M | -4.4M | -898K | 2.99M | 11.75M | 13.36M | 5.39M | 9.09M |
Pretax Income | -244.77M▲ 0% | -53.58M▲ 78.1% | -95.78M▼ 78.8% | -130.84M▼ 36.6% | -134.79M▼ 3.0% | -124.78M▲ 7.4% | -9.65M▲ 92.3% | -107.85M▲ 0% |
Pretax Margin % | - | - | - | -2516.66% | -6030.96% | -1893.7% | -8.84% | - |
Income Tax | 0 | 0 | 43K | 91K | 1.88M | 1.79M | -68K | -68K |
Effective Tax Rate % | 0% | 0% | -0.04% | -0.07% | -1.4% | -1.43% | 0.7% | 0.06% |
Net Income | -244.77M▲ 0% | -53.58M▲ 78.1% | -95.82M▼ 78.9% | -130.93M▼ 36.6% | -136.67M▼ 4.4% | -126.57M▲ 7.4% | -9.58M▲ 92.4% | -107.78M▲ 0% |
Net Margin % | - | - | - | -2518.41% | -6115.12% | -1920.87% | -8.78% | - |
Net Income Growth % | - | 78.11% | -78.86% | -36.64% | -4.38% | 7.4% | 92.43% | -391.11% |
Net Income (Continuing) | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M | -107.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.49▲ 0% | -1.00▲ 77.7% | -1.74▼ 74.0% | -2.27▼ 30.5% | -2.30▼ 1.3% | -1.61▲ 30.0% | -0.11▲ 93.2% | -1.25▲ 0% |
EPS Growth % | - | 77.73% | -74% | -30.46% | -1.32% | 30% | 93.17% | -290.63% |
EPS (Basic) | -4.49 | -1.00 | -1.74 | -2.27 | -2.30 | -1.61 | -0.11 | - |
Diluted Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M | 86.56M |
Basic Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M | 86.56M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IPSC Balance Sheet
Century Therapeutics, Inc. (IPSC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 84.12M | 78.8M | 228.15M | 319.72M | 176.99M | 194.05M | 120.77M | 139.04M |
Cash & Short-Term Investments | 81.54M | 75.75M | 222.88M | 315.5M | 172.74M | 189.29M | 117.11M | 134.8M |
Cash Only | 44.06M | 27.21M | 56.45M | 84.27M | 47.32M | 58.44M | 61.85M | 51.05M |
Short-Term Investments | 37.48M | 48.54M | 166.43M | 231.23M | 125.41M | 130.85M | 55.26M | 83.75M |
Accounts Receivable | 123K | 908K | 250K | 780K | 665K | 1.52M | 667K | 0 |
Days Sales Outstanding | - | - | - | 54.76 | 108.6 | 84.2 | 2.23 | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 320K | 1.8M | 2.79M | 462K | 1.78M | 860K | 2.99M | 4.24M |
Total Non-Current Assets | 6.77M | 27.98M | 209.22M | 166.82M | 183.7M | 159.16M | 102.94M | 187.51M |
Property, Plant & Equipment | 2.49M | 24.78M | 69.82M | 111.73M | 92.08M | 90.85M | 66.17M | 68.58M |
Fixed Asset Turnover | - | - | - | 0.05x | 0.02x | 0.07x | 1.65x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 9.39M | 0 | 0 | 0 | 34.2M | 34.2M | 34.2M |
Long-Term Investments | 4.08M | 1.05M | 135.91M | 51.85M | 91.08M | 30.82M | 2.36M | 89.53M |
Other Non-Current Assets | 206K | -7.24M | 3.49M | 3.24M | 541K | 3.3M | 211K | 2.57M |
Total Assets | 90.9M▲ 0% | 106.78M▲ 17.5% | 437.38M▲ 309.6% | 486.54M▲ 11.2% | 360.69M▼ 25.9% | 353.22M▼ 2.1% | 223.7M▼ 36.7% | 326.55M▲ 0% |
Asset Turnover | - | - | - | 0.01x | 0.01x | 0.02x | 0.49x | 0.00x |
Asset Growth % | - | 17.47% | 309.62% | 11.24% | -25.87% | -2.07% | -36.67% | -101.87% |
Total Current Liabilities | 2.99M | 12.11M | 15.65M | 29.82M | 17.85M | 129.78M | 20.23M | 13.57M |
Accounts Payable | 1.55M | 8.08M | 7.6M | 5.45M | 2.74M | 3.08M | 4.77M | 3.15M |
Days Payables Outstanding | 2.27K | 1.68K | 605.09 | - | - | - | 132.98 | 417.61 |
Short-Term Debt | 0 | 0 | 1.04M | 6.5M | 1.51M | 0 | 3.32M | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 7.15M | 4.37M | 109.16M | 0 | 0 |
Other Current Liabilities | 53K | 52K | 1.08M | 3.17M | 2.72M | 82K | 12.13M | 10.42M |
Current Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x | 5.97x | 10.25x |
Quick Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x | 5.97x | 10.25x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 179.76M | 201.08M | 25.48M | 153.99M | 158.09M | 62.07M | 44.54M | 48.24M |
Long-Term Debt | 0 | 9.64M | 8.9M | 3.74M | 0 | 0 | 0 | 43.94M |
Capital Lease Obligations | 0 | 11.68M | 14.56M | 38.7M | 46.66M | 48.96M | 40.24M | 128.01M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 4.37M | 4.3M | 17.35M |
Other Non-Current Liabilities | 179.76M | 179.76M | 2.02M | 718K | 56K | 8.74M | 0 | 0 |
Total Liabilities | 182.75M | 213.19M | 41.14M | 183.81M | 175.94M | 191.85M | 64.77M | 61.81M |
Total Debt | 0 | 21.55M | 25.12M | 49.41M | 48.17M | 53.83M | 43.56M | 43.94M |
Net Debt | -44.06M | -5.66M | -31.33M | -34.85M | 847K | -4.61M | -18.29M | -7.11M |
Debt / Equity | - | - | 0.06x | 0.16x | 0.26x | 0.33x | 0.27x | 0.17x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.42x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.07x |
Interest Coverage | - | -139.62x | -74.12x | - | -248.61x | - | - | - |
Total Equity | -91.86M▲ 0% | -106.41M▼ 15.8% | 396.24M▲ 472.4% | 302.74M▼ 23.6% | 184.75M▼ 39.0% | 161.36M▼ 12.7% | 158.94M▼ 1.5% | 264.74M▲ 0% |
Equity Growth % | - | -15.84% | 472.36% | -23.6% | -38.97% | -12.66% | -1.5% | -6.77% |
Book Value per Share | -1.68 | -1.94 | 7.20 | 5.24 | 3.11 | 2.05 | 1.84 | 3.06 |
Total Shareholders' Equity | -91.86M | -106.41M | 396.24M | 302.74M | 184.75M | 161.36M | 158.94M | 264.74M |
Common Stock | 1K | 1K | 5K | 6K | 6K | 9K | 9K | 18K |
Retained Earnings | -238.77M | -292.34M | -388.17M | -519.1M | -655.77M | -782.34M | -791.92M | -813.56M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3K | -3K | -650K | -2.46M | 108K | 324K | 30K | -585K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IPSC Cash Flow Statement
Century Therapeutics, Inc. (IPSC) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.17M | -41.27M | -89M | 14.05M | -88.35M | -110.14M | -103.88M | -94.5M |
Operating CF Margin % | - | - | - | 270.28% | -3952.93% | -1671.5% | -95.16% | - |
Operating CF Growth % | - | -155.25% | -115.66% | 115.79% | -728.72% | -24.66% | 5.68% | 69.47% |
Net Income | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M | -107.78M |
Depreciation & Amortization | 249K | 1.4M | 3.75M | 8.44M | 13.04M | 13.3M | 13.1M | 12.88M |
Stock-Based Compensation | 147K | 876K | 4.66M | 10.67M | 14.62M | 12.69M | 6.84M | 4.41M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 870K | -73K | -73K |
Other Non-Cash Items | 225.95M | 5.17M | 1.21M | 1.93M | 11.28M | -1.15M | 389K | 597K |
Working Capital Changes | 2.26M | 4.86M | -2.8M | 123.94M | 9.38M | -9.28M | -114.55M | -4.53M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.23M | 2.06M | -1.85M | -4.79M | -2.36M | -1.47M | 1.56M | -424K |
Cash from Investing | -19.83M | -22.76M | -298.34M | -13.13M | 61.13M | 47.48M | 107.5M | -33.04M |
Capital Expenditures | -2.46M | -9.82M | -44.97M | -30.6M | -13.74M | -154K | -848K | -1.41M |
CapEx % of Revenue | - | - | - | 588.65% | 614.59% | 2.34% | 0.78% | - |
Acquisitions | 0 | 0 | 0 | -238.22M | 0 | -9.61M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 24.17M | -4.72M | 0 | 238.22M | 0 | 0 | 210.7M | -4.25M |
Cash from Financing | 74.84M | 47.69M | 417.77M | 27.16M | -9.72M | 74.56M | 173K | 126.68M |
Debt Issued (Net) | 0 | 9.73M | 0 | 0 | -10.24M | 0 | 0 | 0 |
Equity Issued (Net) | 74.84M | 0 | 381.24M | 27.16M | 516K | 74.56M | 173K | 126.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 37.96M | 36.53M | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | 38.84M▲ 0% | -16.34M▼ 142.1% | 30.43M▲ 286.3% | 28.08M▼ 7.7% | -36.94M▼ 231.5% | 11.91M▲ 132.2% | 3.8M▼ 68.1% | -883K▲ 0% |
Free Cash Flow | -18.63M▲ 0% | -51.09M▼ 174.3% | -133.97M▼ 162.2% | -16.55M▲ 87.6% | -102.08M▼ 516.7% | -110.29M▼ 8.0% | -104.72M▲ 5.0% | -95.91M▲ 0% |
FCF Margin % | - | - | - | -318.37% | -4567.52% | -1673.84% | -95.93% | - |
FCF Growth % | - | -174.29% | -162.21% | 87.65% | -516.75% | -8.04% | 5.05% | 15.96% |
FCF per Share | -0.34 | -0.93 | -2.44 | -0.29 | -1.72 | -1.40 | -1.21 | -1.11 |
FCF Conversion (FCF/Net Income) | 0.07x | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x | 10.84x | 0.89x |
Interest Paid | 0 | 0 | 0 | 1.1M | 586K | 0 | 0 | 0 |
Taxes Paid | 0 | 207K | 983K | 1.1M | 3.11M | 501K | 0 | -2K |
IPSC Key Ratios
Century Therapeutics, Inc. (IPSC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -66.13% | -37.46% | -56.07% | -73.14% | -5.98% | -53.23% |
Return on Invested Capital (ROIC) | - | -56.29% | -31.72% | -48.47% | -60.52% | -7.59% | -45.65% |
Gross Margin | - | - | 100% | 100% | 100% | 88% | - |
Net Margin | - | - | -2518.41% | -6115.12% | -1920.87% | -8.78% | - |
Debt / Equity | - | 0.06x | 0.16x | 0.26x | 0.33x | 0.27x | 0.17x |
Interest Coverage | -139.62x | -74.12x | - | -248.61x | - | - | - |
FCF Conversion | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x | 10.84x | 0.89x |
Revenue Growth | - | - | - | -57.01% | 194.81% | 1556.76% | -100% |
Related:IPSC Dividend History·IPSC Revenue History·IPSC Price History·IPSC P/E History·IPSC Financial Ratios·IPSC Institutional Holders
IPSC SEC Filings & Documents
Century Therapeutics, Inc. (IPSC) SEC filings — annual & quarterly reports (10-K, 10-Q)
IPSC Frequently Asked Questions
Century Therapeutics, Inc. (IPSC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Century Therapeutics, Inc. (IPSC) reported $109.2M in revenue for fiscal year 2025.
Century Therapeutics, Inc. (IPSC) grew revenue by 1556.8% over the past year. This is strong growth.
Century Therapeutics, Inc. (IPSC) reported a net loss of $107.8M for fiscal year 2025.
Dividend & Returns
Century Therapeutics, Inc. (IPSC) has a return on equity (ROE) of -6.0%. Negative ROE indicates the company is unprofitable.
Century Therapeutics, Inc. (IPSC) had negative free cash flow of $95.9M in fiscal year 2025, likely due to heavy capital investments.